Three general guidelines are used to classify the severity of neutropenia based on the ANC (expressed below in cells/µl):
Mild neutropenia (1000 <= ANC < 1500): minimal risk of infection
Moderate neutropenia (500 <= ANC < 1000): moderate risk of infection
Severe neutropenia (ANC < 500): severe risk of infection.Each of these are either derived from laboratory tests or via the formula below:
ANC = 
  
    
      
        
          (
          %
          n
          e
          u
          t
          r
          o
          p
          h
          i
          l
          s
          +
          %
          b
          a
          n
          d
          s
          )
          ×
          (
          W
          B
          C
          )
        
        
          (
          100
          )
        
      
    
    {\displaystyle (\%neutrophils+\%bands)\times (WBC) \over (100)}

Treatment
A fever, when combined with profound neutropenia (febrile neutropenia), is considered a medical emergency and requires broad spectrum antibiotics.
Lower doses again are called for in the elderly to reduce the incidence of side effects and maintain age-dependent normal levels of IGF-1.In many countries, including the UK, the majority view among endocrinologists is that the failure of treatment to provide any demonstrable, measurable benefits in terms of outcomes means treatment is not recommended for all adults with severe GHD, and national guidelines in the UK as set out by NICE suggest three criteria which all need to be met for treatment to be indicated:

Severe GH deficiency, defined as a peak GH response of <9mU/litre during an insulin tolerance test
Perceived impairment of quality of life, as assessed by questionnaire
They are already treated for other pituitary hormone disordersWhere treatment is indicated, duration is dependent upon indication. Cost of adult treatment in the UK is 3000-4000 GBP annually. Side effects
Headaches
Joint pain and muscle pain
Fluid retention, and carpal tunnel syndrome
Mild hypertension
Visual problems
Nausea and vomiting
Paraesthesiae
Antibody formation
Reactions at the injection site
Rarely, benign intracranial hypertension. Prognosis
Child
When treated with GH, a severely deficient child will begin to grow faster within months. In the first year of treatment, the rate of growth may increase from half as fast as other children are growing to twice as fast (e.g., from 1 inch a year to 4 inches, or 2.5 cm to 10). Growth typically slows in subsequent years, but usually remains above normal so that over several years a child who had fallen far behind in his height may grow into the normal height range. Excess adipose tissue may be reduced.